Tobramycin inhalation powder regulatory update

FDA's Anti-Infective Drugs Advisory Committee voted 13-1 that Novartis demonstrated adequate evidence of safety and evidence to support the use of tobramycin inhalation powder for the management of cystic

Read the full 298 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE